On February 2, 2026, Dr. Zheng Jinzhong, founder and chairman of the board of directors of the Greater China Cancer Foundation, Mr. Ho Junfeng, chief honorary president of the Greater China Cancer Foundation, Dr. Fan Jingwen, senior advisor of the Medical and Health Bureau of the Hong Kong SAR Government (Director's Office), Dr. Zhuo Jialiang, consultant physician of the Hong Kong Children's Hospital, and Dr. Wang Shaoming, consultant physician of the Department of Internal Medicine of the Prince of Wales Hospital, Hong Kong, visited Shenzhen Cell Valley and Shenzhen-Hong Kong Cell Valley for exchanges.Dr. Shi Yuanyuan, chairman and general manager of Shenzhen Cell Valley, Dr. Wang Jianxun, chief scientist, and Ms. Tang Xiaomeng, general manager of Shenzhen-Hong Kong Cell Valley, warmly received the guests.The two parties conducted in-depth exchanges around the clinical transformation of cell and gene therapy, Shenzhen-Hong Kong collaboration mechanism and cross-border delivery practices, and jointly discussed how cutting-edge biomedical technologies can serve the clinic more efficiently and benefit patients.

During the event, the visiting guests visited Shenzhen Cell Valley’s smart exhibition hall and clinical-grade GMP production workshop, and systematically understood Cell Valley’s core technology platform and large-scale preparation capabilities in the fields of immune cells, stem cells, and viral vectors.Dr. Wang Jianxun, chief scientist of Shenzhen Cell Valley, said that Cell Valley relies on its internationally benchmarked quality management system and mature industrialization capabilities to have the ability to stably and compliantly produce clinical-grade cell products. With the support of regulatory authorities and customs, Cell Valley has taken the lead in achieving compliant cross-border delivery of cell products.

Subsequently, the guests went to the Shenzhen-Hong Kong Cell Valley located in the Qianhai Free Trade Zone to gain an in-depth understanding of its overall layout and operation model as a "Shenzhen-Hong Kong collaborative clinical transformation platform".With "Shenzhen R&D and preparation, Hong Kong clinical application" as the core path, this platform opens up the key links of cell therapy products from R&D and production to cross-border delivery and clinical use, providing a realistic and feasible solution for Hong Kong hospitals to introduce high-quality and sustainable cell therapy technology.

During the exchange, three Hong Kong clinical experts said that this Shenzhen-Hong Kong cooperation model, which relies on the mainland's advanced manufacturing capabilities and accurately meets Hong Kong's clinical needs, will help accelerate the application of innovative treatment technologies in hospitals, and is especially important for patients with tumors, rare diseases, and children with major diseases.Dr. Fan Jingwen of the Hong Kong Medical Bureau stated that he fully supports Hong Kong public hospitals in launching clinical research on cell gene therapy as soon as possible, supports Cell Valley to cooperate closely with major hospitals in Hong Kong, and invites Shenzhen Cell Valley to build a GMP-level cell preparation center in Hong Kong to serve Hong Kong, radiate the Southeast Asian market, and help Hong Kong become an international medical tourism center city.Dr. Zheng Jinzhong, Chairman of the Greater China Cancer Foundation, also believes that this model is expected to allow more patients to benefit from cutting-edge cell therapy technology in a more accessible way.

Dr. Shi Yuanyuan, chairman of Shenzhen Cell Valley, said that in the future, it will continue to leverage its comprehensive advantages in underlying cell and gene therapy technologies, GMP preparation systems and international compliance. With the support of customs and relevant regulatory authorities, it will continue to improve cross-border delivery and clinical transformation mechanisms, deepen collaborative cooperation with Hong Kong medical institutions and public welfare organizations, promote more innovative results to truly go to the clinic, serve hospitals, and benefit Hong Kong residents, and inject continuous impetus into the high-quality development of the life and health industry in the Guangdong-Hong Kong-Macao Greater Bay Area.

微信公众号

市场部：赖女士